NDAINHALATIONAEROSOL, METERED
Approved
Nov 2018
Lifecycle
Post-LOE
Competitive Pressure
35/100
Data completeness
3/8 — Basic
PRIMATENE MIST (epinephrine inhalation) by Pfizer is adrenergic alpha-agonists [moa]. First approved in 2018.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Primatene Mist is a metered-dose inhaled epinephrine product approved in 2018 for acute bronchospasm relief in patients with reversible obstructive airway disease. It works as an alpha-adrenergic agonist, stimulating adrenergic receptors to rapidly dilate airways and restore breathing. This is an over-the-counter rescue therapy positioned for emergency use in asthma and COPD patients.
Post-LOEPost-LOE
Product is in post-LOE phase with moderate competitive pressure (35/100), signaling a mature market with smaller brand teams focused on maintenance and cost management.
Mechanism of Action
Adrenergic alpha-Agonists
Pharmacologic Class:
alpha-Adrenergic Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Worked on PRIMATENE MIST at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.